Author： Lassi Kiran Dawson Nancy A
Publisher： Future Medicine
ISSN： 1479-6694
Source： Future Oncology, Vol.7, Iss.4, 2011-04, pp. : 551-558
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Prostate cancer represents a third of all newly diagnosed cancers in men in the USA with an estimated incidence of 192,280 cases and 27,360 deaths in 2009. It continues to be a major cause of cancer-related morbidity and mortality, and there is an urgent need for new treatments. Historically, systemic therapy options were limited after progression on docetaxel-based chemotherapy. This article reviews current data on the novel therapeutics demonstrating activity in metastatic castration-resistant prostate cancer and their future role in the treatment of this disease with a poor prognosis.
Related content
Access to resources
Recommend
Molecular mechanisms of castration-resistant prostate cancer progression
Future Oncology, Vol. 5, Iss. 9, 2009-11 ,pp. :